SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ICOS Corporation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tktrimbath who wrote (977)5/3/2003 7:32:44 AM
From: AJAG  Read Replies (2) of 1139
 
Re valuation of 1.5 billion-
Amgen's valuation is 70 billion; Johnson & Johnson is well over 200 billion; Genentech is over 6 billion. The company has 300 million in cash, other products in progress and a potential blockbuster drug already appproved in 30 countries. I do not see the "overvaluation" issue. The stock is "risky" perhaps, bur not overvalued. By the way, how many high profile drugs are sold in the European countries, but have not been approved for US sale? The issue here is eventual market share.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News